376 related articles for article (PubMed ID: 15670612)
21. Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.
Lu D; Dopart R; Kendall DA
Cell Stress Chaperones; 2016 Jan; 21(1):1-7. PubMed ID: 26498013
[TBL] [Abstract][Full Text] [Related]
22. Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade.
Crespillo A; Suárez J; Bermúdez-Silva FJ; Rivera P; Vida M; Alonso M; Palomino A; Lucena MA; Serrano A; Pérez-Martín M; Macias M; Fernández-Llébrez P; Rodríguez de Fonseca F
Biochem J; 2011 Jan; 433(1):175-85. PubMed ID: 20955176
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.
Bátkai S; Pacher P; Járai Z; Wagner JA; Kunos G
Am J Physiol Heart Circ Physiol; 2004 Aug; 287(2):H595-600. PubMed ID: 15059774
[TBL] [Abstract][Full Text] [Related]
24. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors.
Govaerts SJ; Muccioli GG; Hermans E; Lambert DM
Eur J Pharmacol; 2004 Jul; 495(1):43-53. PubMed ID: 15219819
[TBL] [Abstract][Full Text] [Related]
26. Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists.
Dhopeshwarkar A; Murataeva N; Makriyannis A; Straiker A; Mackie K
J Pharmacol Exp Ther; 2017 Feb; 360(2):300-311. PubMed ID: 27927913
[TBL] [Abstract][Full Text] [Related]
27. Blocking the cannabinoid receptors: drug candidates and therapeutic promises.
Muccioli GG
Chem Biodivers; 2007 Aug; 4(8):1805-27. PubMed ID: 17712820
[TBL] [Abstract][Full Text] [Related]
28. Differential role of the hippocampal endocannabinoid system in the memory consolidation and retrieval mechanisms.
De Oliveira Alvares L; Genro BP; Diehl F; Quillfeldt JA
Neurobiol Learn Mem; 2008 Jul; 90(1):1-9. PubMed ID: 18342551
[TBL] [Abstract][Full Text] [Related]
29. The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA(A) receptors.
Baur R; Gertsch J; Sigel E
Br J Pharmacol; 2012 Apr; 165(8):2479-84. PubMed ID: 21470203
[TBL] [Abstract][Full Text] [Related]
30. Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors.
Reggio PH
Curr Pharm Des; 2003; 9(20):1607-33. PubMed ID: 12871061
[TBL] [Abstract][Full Text] [Related]
31. Differential effect of cannabinoid agonists and endocannabinoids on histamine release from distinct regions of the rat brain.
Cenni G; Blandina P; Mackie K; Nosi D; Formigli L; Giannoni P; Ballini C; Della Corte L; Mannaioni PF; Passani MB
Eur J Neurosci; 2006 Sep; 24(6):1633-44. PubMed ID: 17004927
[TBL] [Abstract][Full Text] [Related]
32. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.
Janero DR; Makriyannis A
Expert Opin Emerg Drugs; 2009 Mar; 14(1):43-65. PubMed ID: 19249987
[TBL] [Abstract][Full Text] [Related]
33. Effects of endocannabinoid 1 and 2 (CB1; CB2) receptor agonists on luteal weight, circulating progesterone, luteal mRNA for luteinizing hormone (LH) receptors, and luteal unoccupied and occupied receptors for LH in vivo in ewes.
Tsutahara NM; Weems YS; Arreguin-Arevalo JA; Nett TM; LaPorte ME; Uchida J; Pang J; McBride T; Randel RD; Weems CW
Prostaglandins Other Lipid Mediat; 2011 Feb; 94(1-2):17-24. PubMed ID: 21109016
[TBL] [Abstract][Full Text] [Related]
34. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
Després JP
Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
[TBL] [Abstract][Full Text] [Related]
35. Pharmacology of cannabinoid receptor ligands.
Pertwee RG
Curr Med Chem; 1999 Aug; 6(8):635-64. PubMed ID: 10469884
[TBL] [Abstract][Full Text] [Related]
36. Estradiol decreases cortical reactive astrogliosis after brain injury by a mechanism involving cannabinoid receptors.
López Rodríguez AB; Mateos Vicente B; Romero-Zerbo SY; Rodriguez-Rodriguez N; Bellini MJ; Rodriguez de Fonseca F; Bermudez-Silva FJ; Azcoitia I; Garcia-Segura LM; Viveros MP
Cereb Cortex; 2011 Sep; 21(9):2046-55. PubMed ID: 21258044
[TBL] [Abstract][Full Text] [Related]
37. Inverse agonism of cannabinoid CB1 receptor blocks the adhesion of encephalitogenic T cells in inflamed brain venules by a protein kinase A-dependent mechanism.
Rossi B; Zenaro E; Angiari S; Ottoboni L; Bach S; Piccio L; Pietronigro EC; Scarpini E; Fusco M; Leon A; Constantin G
J Neuroimmunol; 2011 Apr; 233(1-2):97-105. PubMed ID: 21216016
[TBL] [Abstract][Full Text] [Related]
38. Crystal Structure of the Human Cannabinoid Receptor CB2.
Li X; Hua T; Vemuri K; Ho JH; Wu Y; Wu L; Popov P; Benchama O; Zvonok N; Locke K; Qu L; Han GW; Iyer MR; Cinar R; Coffey NJ; Wang J; Wu M; Katritch V; Zhao S; Kunos G; Bohn LM; Makriyannis A; Stevens RC; Liu ZJ
Cell; 2019 Jan; 176(3):459-467.e13. PubMed ID: 30639103
[TBL] [Abstract][Full Text] [Related]
39. The cannabinoid ligands SR141716A and AM251 enhance human and mouse islet function via GPR55-independent signalling.
Ruz-Maldonado I; Liu B; Atanes P; Pingitore A; Huang GC; Choudhary P; Persaud SJ
Cell Mol Life Sci; 2020 Nov; 77(22):4709-4723. PubMed ID: 31925452
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacology of cannabinoid receptors].
Le Fur G; Rinaldi-Carmona M; Barth F; Alexander J
Bull Acad Natl Med; 2007; 191(4-5):933-8; discussion 938-40. PubMed ID: 18225447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
